Juniper Pharma (JNP) Tops Q4 EPS by 43c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Juniper Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial and Operating Results
March 7, 2017 6:00 AM ESTBOSTON, March 7, 2017 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today announced financial results for the three- and twelve-month periods ended December 31, 2016. Recent highlights include:
Advanced lead formulations for three intravaginal ring ("IVR") candidates: JNP-0101 (oxybutynin IVR) for overactive bladder in women, JNP-0201 (estradiol + natural progesterone IVR) for symptoms of menopause, and JNP-0301 (natural progesterone IVR) for the prevention of preterm birth ("PTB") in women with a short cervical length at... More